0000899243-22-032655.txt : 20221004
0000899243-22-032655.hdr.sgml : 20221004
20221004161548
ACCESSION NUMBER: 0000899243-22-032655
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221001
FILED AS OF DATE: 20221004
DATE AS OF CHANGE: 20221004
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Harding Thomas C.
CENTRAL INDEX KEY: 0001834833
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35347
FILM NUMBER: 221291744
MAIL ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY, SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clovis Oncology, Inc.
CENTRAL INDEX KEY: 0001466301
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 900475355
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: (303) 625-5000
MAIL ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-10-01
0
0001466301
Clovis Oncology, Inc.
CLVS
0001834833
Harding Thomas C.
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100
BOULDER
CO
80301
0
1
0
0
See Remarks
Common Stock
2022-10-01
4
M
0
15
A
3689
I
By wife
Common Stock
2022-10-03
4
S
0
6
1.29
D
3683
I
By wife
Common Stock
17816
D
Restricted Stock Units
2022-10-01
4
M
0
15
0.00
D
Common Stock
15
109
I
By wife
Each Restricted Stock Unit represents the right to receive one share of Common Stock.
Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
On July 1, 2020, the reporting person's wife was granted 250 Restricted Stock Units. 25% of such Restricted Stock Units vested on July 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
Senior Vice President and Chief Scientific Officer
/s/ Thomas Harding
2022-10-03